Treatment of Moderately Severe Essential Hypertension in General Practice with a Combination of Cyclopenthiazide with Potassium Chloride (Navidrex K) and Oxprenolol (Trasicor 80mg): A Report on 554 Patients

1974 ◽  
Vol 2 (1) ◽  
pp. 7-11 ◽  
Author(s):  
W A Forrest
Keyword(s):  
Blood Pressure ◽  
General Practice ◽  
Essential Hypertension ◽  
Side Effects ◽  
Potassium Chloride ◽  
Maximum Dose ◽  
Diastolic Pressure ◽  
Good Control ◽  
Daily Dose

Five hundred and fifty-four patients, with an initial mean diastolic pressure of 130 mm Hg, were treated with a combination of Navidrex K ( 0·5 mg daily) and up to 480 mg (six tablets daily) of Oxprenolol (Trasicor 80 mg). In 69% of this group, good control of the blood pressure was achieved with a daily dose of four tablets ( 320 mg) of Oxprenolol. In the remainder of patients significant reductions in blood pressure levels were noted, again with a mean dose of less than 320 mg daily of oxprenolol. There were indications in this group that better control of blood pressure levels might have been reached, had more of the patients been prescribed the maximum dose of 480 mg daily (six tablets) permitted in the study. Tolerability of this regime was very good. More than 80% of patients reported no side-effects at all, and one patient in four reported ‘feeling better’ after treatment.

Prestim in the Management of Mild to Moderate Essential Hypertension in General Practice

1983 ◽  
Vol 11 (3) ◽  
pp. 186-189 ◽  
Author(s):  
K Peacock ◽  
B Hodge
Keyword(s):  
Blood Pressure ◽  
Side Effects ◽  
Maximum Dose ◽  
Fixed Dose ◽  
Dose Titration ◽  
Timolol Maleate ◽  
Daily Dose ◽  
Dose Combination ◽  
Lost To Follow Up

Fifty-three hypertensive patients from one practice, of whom forty-two were new patients, were treated with Prestim — a fixed dose combination of 10 mg timolol maleate and 2·5 mg bendrofluazide. After a 2-week placebo run-in period, dose titration took place at weekly intervals up to a maximum of 4 tablets daily. Stabilized patients were followed-up at 3 months and approximately 1 year. At the 3-month follow-up, forty-nine patients were evaluated. Forty-two patients (85%) were well controlled (diastolic blood pressure below 95 mm Hg) on Prestim at a mean daily dose of 1·4 tablets. Four patients stopped therapy due to side-effects and in three patients the blood pressure was uncontrolled on the maximum dose of 4 tablets daily. After 1 year, thirty-four patients (75%) were still well controlled on a mean dose of 1·3 tablets daily. A further two patients were lost to follow-up and six other patients stopped therapy during the last nine months of the study. There were no unexpected side-effects and the general biochemical profile remained unaltered.

A Multicentre Study Examining the Substitution of Trasidrex for the Free Combination of Slow-Trasicor and Navidrex-K

1979 ◽  
Vol 7 (6) ◽  
pp. 524-527 ◽  
Author(s):  
A F Ebbutt ◽  
R W Elsdon Dew
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
General Practice ◽  
Essential Hypertension ◽  
Side Effects ◽  
Open Study ◽  
Global Assessment ◽  
Pressure Control ◽  
Time Intervals ◽  
The Mean

A multicentre, open study of general practice patients with essential hypertension who were currently being treated with oxprenolol and cyclopenthiazide was undertaken in which the patients were transferred to Trasidrex for 12 weeks. Weight, blood pressure, heart rate and side-effects were assessed pre-trial and at 4-week intervals. A global assessment was also made at the same time intervals. The mean serum potassium remained virtually unchanged after 12 weeks treatment with Trasidrex. Blood pressure control was marginally improved during the study and it is thought possible that better patient compliance might explain this. Trasidrex was tolerated equally as well as the free combination.

Piretanide, a Potassium Stable Diuretic, in the Treatment of Essential Hypertension: A Double-Blind Comparison of Two Formulations

1985 ◽  
Vol 13 (1) ◽  
pp. 31-39 ◽  
Author(s):  
W Dols ◽  
M Verho ◽  
B Rangoonwala ◽  
S Jaeger
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Side Effects ◽  
Slow Release ◽  
Diastolic Pressure ◽  
Serum Magnesium ◽  
Tablet Formulation ◽  
Blood Pressure Lowering Effect ◽  
Double Blind ◽  
Significant Difference

In a randomized double-blind parallel group study the effects of two formulations of piretanide (standard tablet and slow-release capsule) were compared in patients with mild to moderate essential hypertension. Forty patients entered the study and thirty-seven completed it. Both formulations of piretanide produced a significant reduction in erect and supine blood pressure which was evident at 2 weeks and was maintained and further enhanced over the ensuing trial period. A mean maximal fall in supine diastolic pressure of 22% was observed in the piretanide tablet group, and of 20% in the slow-release piretanide group. Blood pressure fell more quickly at the beginning of treatment with the tablet preparation, such that there was a significant difference between the groups up to the fourth week. After this point the blood pressure lowering effect was very similar in both groups and there was a progressive reduction in supine blood pressures over the 12-week active-treatment period. Slow-release piretanide produced a smoother effect than the tablet formulation. There were no significant changes in serum potassium and serum magnesium in either treatment group. Minor changes were seen in some other biochemical and haematological variables but these were of no clinical significance. Three patients were withdrawn from the study because of side-effects: one because of an excessive antihypertensive response to the tablet formulation; and two because of allergic reactions to the slow-release preparation. Side-effects were otherwise mild and infrequent.

Alprenolol in Hypertension: An Open Assessment in General Practice

1975 ◽  
Vol 3 (5) ◽  
pp. 338-344 ◽  
Author(s):  
F L Madill ◽  
G Nyberg
Keyword(s):  
Blood Pressure ◽  
General Practice ◽  
Side Effects ◽  
Side Effect ◽  
Open Study ◽  
Diastolic Pressure ◽  
Beta Blockers ◽  
Previous Treatment ◽  
Average Dose ◽  
Average Systolic Blood Pressure

In an open study of alprenolol for hypertension in 100 patients and involving 29 practitioners, the drug was found to he capable of controlling blood pressure to a level of 120 mm Hg mean blood pressure in 79 patients, either alone or in combination with other drugs, at an average dose of 359 mg daily. The average systolic blood pressure fell from 186 to 157 mm Hg, and the average diastolic pressure fell from 112 to 95 mm Hg over 8-12 weeks. Three patients had to withdraw from treatment due to side-effects. Thirteen patients had side-effects of tolerable nature, and 16 patients with side-effects of similar severity on previous treatment suffered less or not at all when switched to alprenolol. These results are very similar to other studies of the same type using other beta-blockers, but the side-effect frequency seems to be lower with alprenolol. This is corroborated by comparative official side-effect reporting over seven years for different beta-blockers.

The Use of Timolol/Bendrofluazide (Prestim) in the Treatment of Hypertensive Patients Failing to Respond to other Antihypertensives

1983 ◽  
Vol 11 (6) ◽  
pp. 359-363 ◽  
Author(s):  
R Ellis ◽  
S J T Wood
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Diastolic Blood Pressure ◽  
Adverse Reactions ◽  
Maximum Dose ◽  
Beta Blockers ◽  
Moderate Essential Hypertension ◽  
Hypertensive Patients ◽  
Previous Therapy ◽  
Daily Dose

This study was designed to assess the effectiveness of a timolol/bendrofluazide combination (Prestim®) in mild to moderate essential hypertension in patients not achieving control of blood pressure on a variety of drugs used alone or in combination (methyldopa, diuretics, beta-blockers, etc.). Normotension (diastolic blood pressure <95 mm Hg) was achieved in sixty-eight out of eighty-four (81%) patients with a mean daily dose of 1·9 tablets. Seven patients stopped therapy because of adverse reactions and eight patients did not respond to the maximum dose of four tablets daily. One other patient, initially controlled on two tablets daily, was uncontrolled at the final assessment. The change-over from previous therapy to Prestim was easily managed and no reports of metabolic disturbance were received. Prestim proved an effective alternative in patients not responding satisfactorily to other antihypertensive therapies.

The Management of Essential Hypertension with Once Daily Administration of Timolol Maleate and Bendrofluazide

1977 ◽  
Vol 5 (2) ◽  
pp. 114-119 ◽  
Author(s):  
R B Deering ◽  
A S Fox ◽  
L J Ison
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Side Effects ◽  
Good Control ◽  
Moderate Essential Hypertension ◽  
Daily Regimen ◽  
Timolol Maleate ◽  
Once Daily ◽  
Starting Dose ◽  
Single Blind

A placebo controlled, single-blind study was performed on new patients presenting with mild to moderate essential hypertension. A once daily combined dose of timolol maleate and bendrofluazide in a 4:1 ratio was administered to each patient after a four week placebo period. The starting dose was timolol 10 mg and bendrofluazide 2·5 mg and this dose was increased in steps of timolol 10 mg and bendrofluazide 2·5 mg until blood pressure was controlled. Eleven out of twelve patients achieved normotension, the falls in diastolic and systolic blood pressure being highly significant on active treatment compared with placebo. The once daily regimen of timolol and bendrofluazide resulted in good control of blood pressure with no more side-effects than occurred on the placebo. A combination of these two drugs in one tablet would appear to be both practical and advantageous and should increase patient compliance in taking medication.

Assessment of the Antihypertensive Effect of Atenolol with 24 H Ambulatory Monitoring of Blood Pressure

1979 ◽  
Vol 57 (s5) ◽  
pp. 387s-389s ◽  
Author(s):  
J. S. Floras ◽  
P. Fox ◽  
M. O. Hassan ◽  
J. V. Jones ◽  
P. Sleight ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Arterial Blood Pressure ◽  
Antihypertensive Effect ◽  
Ambulatory Monitoring ◽  
Single Daily Dose ◽  
Pressure Measurements ◽  
Arterial Blood ◽  
Blood Pressure Study ◽  
Daily Dose

1. Twenty-four hour intra-arterial blood pressure measurements and electrocardiograms were obtained from 12 subjects with untreated essential hypertension. 2. The patients kept records of their activity, paying particular attention to times of retiring to bed, and times of waking in the morning. 3. All subjects were treated with a single daily dose of atenolol (50 to 200 mg) for between 2 and 9 months, and then underwent a second 24 h blood pressure study. 4. Arterial blood pressure was lowered significantly throughout the 24 h period with a single daily dose of atenolol.

A Comparative Trial of Opipramol and Chlordiazepoxide in the Treatment of Anxiety

1973 ◽  
Vol 1 (3) ◽  
pp. 145-150 ◽  
Author(s):  
K Jepson ◽  
G Beaumont
Keyword(s):  
Clinical Trial ◽  
General Practice ◽  
Side Effects ◽  
Rating Scale ◽  
Comparative Trial ◽  
Anxiety Score ◽  
Double Blind ◽  
Somatic Anxiety ◽  
Daily Dose ◽  
The Difference

A daily dose of 200 mg of opipramol (Insidon, Geigy) and 30 mg of chlordiazepoxide (Librium, Roche) were compared in a clinical trial in general practice. The trial was double blind and a stratified randomisation technique was employed. Twenty four patients received opipramol and twenty six chlordiazepoxide for four weeks. A total anxiety score and separate ‘psychic’ anxiety and ‘somatic’ anxiety scores were recorded, using a rating scale initially and after two and four weeks treatment. No overall difference in efficacy was found between the two drugs—opipramol producing a 76% improvement and chlordiazepoxide 64% by the end of the study. There was no difference in the relief of psychic anxiety. Although opipramol appeared to give more relief of somatic anxiety, the difference was not statistically significant. Again although opipramol relieved more individual symptoms than chlordiazepoxide, none of the differences were significant. 70% of patients on opipramol and 74% of those on chlordiazepoxide were classified ‘better’ globally by both doctor and patient by the end of the trial. The total number of side effects recorded was similar on both drugs although drowsiness occurred twice as frequently on chlordiazepoxide as it did on opipramol.

Alcohol: Effect on Blood Pressure and Predisposition to Hypertension

1981 ◽  
Vol 61 (s7) ◽  
pp. 373s-375s ◽  
Author(s):  
P. D. Arkwright ◽  
L. J. Beilin ◽  
I. Rouse ◽  
B. K. Armstrong ◽  
R. Vandongen
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Essential Hypertension ◽  
Alcohol Consumption ◽  
Diastolic Pressure ◽  
Systolic Pressure ◽  
Threshold Effect ◽  
Health Questionnaire ◽  
Government Employees ◽  
Weekly Alcohol Consumption

1. The association between alcohol consumption and blood pressure was studied in 491 Government employees. The men, aged 21–45 years, volunteered to complete a health questionnaire and submitted to standardized measurements of blood pressure, heart rate and body size. 2. Average weekly alcohol consumption correlated with systolic pressure (r = 0.18, P &lt; 0.001) but not with diastolic pressure. Systolic pressure increased progressively with increasing alcohol consumption with no obvious threshold effect. The effect of alcohol was independent of age, obesity (Quetelet's index) or cigarette smoking. 3. Results indicate that alcohol ranks close to obesity as a preventable cause of essential hypertension in the community.

Sign in / Sign up

Export Citation Format

Share Document